Following
Trump’s “hunches” is not enough
The
COVID-19 crisis has revealed the harmful consequences of leaders making
critical decisions based on insufficient data, which end up hurting the most
vulnerable communities.
With
many people impatient to get back to work and businesses eager to re-open, experts
agree that widespread and ongoing diagnostic and antibody testing for COVID-19
are essential for any plan to return to normal.
However, there are major hurdles to overcome, from having accurate data on infections and better demographics data on those most affected, to a better understanding of how the virus spreads and the variation in severity of cases.
Unfortunately,
as some states move to re-open, they are making these decisions in the dark and
putting people's lives at risk.
The
U.S. had a slow start rolling out testing, hindering data on COVID-19
infections early on. The first batch of tests made in mid-February by the Centers
for Disease Control and Prevention (CDC) were unusable because the CDC didn't
follow its own protocol and
contaminated the tests.
Now with ramped up testing, private labs are facing major backlogs because they didn't want to turn away business, even though they lacked the capacity to run all the tests they accepted.
Now with ramped up testing, private labs are facing major backlogs because they didn't want to turn away business, even though they lacked the capacity to run all the tests they accepted.
There
is concern that because most states are not providing information on pending
tests, the extent of outbreaks is being under-reported. Meanwhile, academic
labs are operating below capacity.
Further, the tests require validation, as some have poor accuracy and could dangerously lead to false negatives.
Further, the tests require validation, as some have poor accuracy and could dangerously lead to false negatives.
While
this train wreck is on public display, it's a familiar landscape to those of us
who work in the field of chemical regulation.
The
U.S. Environmental Protection Agency (EPA) routinely makes decisions in the
dark. Its chemical regulation arm approves chemicals, often toxic to humans, to
market without adequate data on safety.
The EPA often assumes lack of data is equivalent to safe. Only if there is a massive tragedy linked to a chemical, such as the effects of lead on brain damage in children, do regulators consider health.
Just
like doctors, businesses, and government leaders today are calling for more
COVID-19 testing before opening up the country, environmental health scientists
routinely call for more chemical safety testing before chemicals are put on the
market.
Currently,
the EPA is conducting risk evaluations for a number of chemicals that have
been in use for decades to decide if they should be withdrawn. Five of the
chemicals in question are linked to breast cancer.
At
the same time, EPA is considering approval of six new PFAS chemicals. PFAS are
a class of "non-stick" chemicals widely used in consumer products
that have been linked with cancer, have contaminated our drinking water, and
are found in the blood of virtually every American.
Last
year the EPA approved three new PFAS, despite incomplete test results, failed
test protocols, and enormous data gaps on the health effects, as we detailed in
our comment to EPA.
As
with COVID-19, what we don't know could literally kill us.
Medical
and environmental racism
What
we do know is that communities of color are being hit harder by
COVID-19. Medical racism, poor
access to good health care, and chronic exposures among essential service
workers are important contributing factors.
However,
a lack of systematic data collection and reporting of racial data is preventing
these communities from receiving the necessary level of care and resources.
These
disparities are common in environmental justice work, where communities of
color experience higher levels of air pollution.
A
renewed focus on prevention
Inadequate
chemical safety regulations, along with a stream of environmental rollbacks
under this administration, will have lasting impacts long after this pandemic
is over.
To
protect ourselves from future pandemics, safeguarding our environment, reducing
hazardous exposures, and building a stronger evidence-based public health
system are essential.
In
2019, just 4 percent of the National Institutes of Health budget went toward prevention. And yet,
as we've seen with COVID-19, prevention is powerful; states that issued stay at
home orders earlier rather than later undoubtedly saved countless more lives.
It
is now clearer than ever that as a society, we need a stronger public health
infrastructure, one that focuses on prevention and relies on sound science to
make decisions.
Kathryn
Rodgers is a staff scientist at Silent Spring Institute, based in Newton,
Massachusetts.